OUR BACKGROUND
Why Etcembly exists
Having contributed to the development of more than 20 FDA-approved drugs, our founding team noticed a universal barrier. Brilliant lab scientists were hindered by a lack of intuitive computational tools, leaving vast scientific potential untapped and slowing innovation. Additionally, only large pharmaceutical companies or well-funded institutes could adopt AI-enabled discovery tools at scale.
In 2020, we started Etcembly to change that and redefine drug development by fusing human ingenuity with artificial intelligence.
OUR MILESTONES
What we’ve built so far
3
TCR and antibody-specific LLMs fine-tuned/created
4
Patents filed
$20M
In funding raised
OUR TEAM
Built by scientists, for scientists
< SWIPE TO SEE MORE >
Michelle Teng
CEO
Co-founder
20 years of experience across pipeline from discovery to translational medicine in Immunocore (KIMMTRAK) & AstraZeneca (FluMist)
Jacob Hurst
CTO
Co-founder
25 years of experience in translational medicine (KIMMTRAK), TCR and antibody repertoire analytics (Abysis)
NICK PUMPHREY
CSO
Over 20 years of experience developing TCR-based therapeutics at Immunocore and Adaptimmune (Afamicel)
MITHI THAYA
Tech Advisor
Experienced tech
founder with multiple
successful exits
JOHN MCCAFFERTY
Scientific Advisor
Serial entrepreneur.
Founder of Cambridge
Antibody Technology,
Maxion Tx, IonTas
NICK CROSS
Chairman
Serial founder and investor
with considerable Board
experience, including
Immunocore,
Adaptimmune, Oxford
Asymmetry and Oxford
Semiconductor Ltd
Bent Jakobsen
Director
TCR therapies pioneer.
Founded Immunocore
and Adaptimmune
CaREERS
Help us shape the future of biologics discovery
Tackling the intractable problems in drug development requires exceptional talent. We are committed to developing the next generation of scientists and welcome motivated individuals who share our vision. If you aspire to break boundaries in precision medicine and can demonstrate an understanding of the convergence of these fields, we are interested in hearing from you.
